Stallergenes bets big on personalized allergy treatment, enters another research collaboration

French Stallergenes Greer is teaming up with researchers from the Imperial College London to identify biomarkers for a precision medicine approach to allergy immunotherapy.

French Stallergenes Greer, a competitor of ALK on the allergy market, has ramped up research in personalized medicine the past few years | Photo: Stallergenes Greer / PR

The right treatment for the right patient at the right time.

That's the goal of a new alliance that has just seen the light of day between French allergy group Stallergenes Greer and the renowned UK-based research institution, Imperial College London.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs